Scientific article

Vitiligo : ce n’est plus une fatalité en 2023

Published inRevue médicale suisse, vol. 19, no. 820, p. 637-641
Publication date2023-03-29

Vitiligo is an acquired auto-inflammatory disorder characterized by a depigmentation. It is a polygenic disease developed in a context of allelic variations. Its pathophysiology is complex, associating intrinsic skin defects, exposome triggering factors and innate then adaptive auto-immune activation leading to the loss of melanocytes. The diagnosis is clinical. Nevertheless, Wood's lamp is mandatory to assess the lesions and their activity, especially in fair-skinned patients. The management of vitiligo is long and aims to halt the depigmentation process and to repigment the affected areas. This requires a combination of immunosuppressive topical or systemic treatment with ultraviolet rays from phototherapy or sun exposure.

  • Humans
  • Vitiligo / therapy
  • Vitiligo / diagnosis
  • Vitiligo / pathology
  • Skin
  • Melanocytes / pathology
  • Immunosuppressive Agents / therapeutic use
Citation (ISO format)
ALVAREZ MARTINEZ, David et al. Vitiligo : ce n’est plus une fatalité en 2023. In: Revue médicale suisse, 2023, vol. 19, n° 820, p. 637–641. doi: 10.53738/REVMED.2023.19.820.637
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 09/30/2024
ISSN of the journal1660-9379

Technical informations

Creation12/22/2023 9:26:02 AM
First validation04/09/2024 8:56:56 AM
Update time04/09/2024 8:56:56 AM
Status update04/09/2024 8:56:56 AM
Last indexation05/06/2024 6:21:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack